Barclays Initiates Coverage on TransMedics Group (NASDAQ:TMDX)

Analysts at Barclays began coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research report issued on Wednesday, Briefing.com reports. The firm set an “overweight” rating and a $120.00 price target on the stock. Barclays‘s price target indicates a potential upside of 49.48% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Tuesday, September 8th. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research note on Friday, September 11th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Finally, Stifel Nicolaus upped their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $121.00.

TransMedics Group Price Performance

Shares of TMDX opened at $80.28 on Wednesday. The firm has a fifty day simple moving average of $85.86 and a two-hundred day simple moving average of $84.45. The firm has a market cap of $2.77 billion, a PE ratio of 20.64, a P/E/G ratio of 1.14 and a beta of 1.94. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. TransMedics Group has a 1-year low of $60.10 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter last year, the business earned $0.92 earnings per share. The business’s quarterly revenue was up 20.7% on a year-over-year basis. On average, equities analysts anticipate that TransMedics Group will post 1.46 EPS for the current year.

Insider Activity

In other TransMedics Group news, Director David Weill bought 1,336 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in TMDX. Braidwell LP boosted its position in shares of TransMedics Group by 85.1% during the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after acquiring an additional 280,324 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in TransMedics Group by 5.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock worth $51,355,000 after purchasing an additional 26,969 shares in the last quarter. Wellington Management Group LLP lifted its stake in TransMedics Group by 6.1% in the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock worth $34,271,000 after purchasing an additional 29,500 shares in the last quarter. Wasatch Advisors LP boosted its holdings in shares of TransMedics Group by 4.3% during the 1st quarter. Wasatch Advisors LP now owns 346,144 shares of the company’s stock valued at $34,410,000 after purchasing an additional 14,296 shares during the last quarter. Finally, Congress Asset Management Co. boosted its holdings in shares of TransMedics Group by 11.0% during the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock valued at $21,109,000 after purchasing an additional 25,118 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.